These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8709175)

  • 21. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
    van der Gaast A; Schoenmakers CH; Kok TC; Blijenberg BG; Cornillie F; Splinter TA
    Br J Cancer; 1994 Mar; 69(3):525-8. PubMed ID: 7510117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Basic and clinical studies on serum cytokeratin 19 fragment assay using Centocor CYFRA 21-1 kit in patients with lung cancer].
    Hamase A; Sugimoto Y; Maeda M; Kitani H; Fukuchi M
    Kaku Igaku; 1994 Aug; 31(8):969-76. PubMed ID: 7523748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.
    Koga H; Eguchi K; Shinkai T; Tamura T; Ohe Y; Oshita F; Saijo N; Kondo H; Oki K; Okura H
    Jpn J Clin Oncol; 1994 Oct; 24(5):263-8. PubMed ID: 7526016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group.
    Rastel D; Ramaioli A; Cornillie F; Thirion B
    Eur J Cancer; 1994; 30A(5):601-6. PubMed ID: 7521651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
    Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
    Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diagnostic and prognostic value of ProGRP in lung cancer.
    Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
    Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of the value of determining levels of cytokeratin-19 fragments for diagnosis of lung cancer].
    Szturmowicz M; Sakowicz A; Wiatr E; Zych J; Załeska J; Rudziński P; Rowińska-Zakrzewska E
    Pneumonol Alergol Pol; 1995; 63(11-12):609-14. PubMed ID: 8616475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients.
    Muley T; Dienemann H; Ebert W
    Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment.
    Sugama Y; Kitamura S; Kawai T; Ohkubo A; Hasegawa S; Kuriyama T; Kato H; Fukuoka M; Ohkawa J
    Jpn J Cancer Res; 1994 Nov; 85(11):1178-84. PubMed ID: 7530241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum tumor marker CYFRA 21-1 in the diagnostics of squamous cell lung cancer--comparison with CEA.
    Berzinec P; Zuffová H; Letkovicová M; Arpásová M
    Neoplasma; 1996; 43(3):159-61. PubMed ID: 8841502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC.
    Muley T; Fetz TH; Dienemann H; Hoffmann H; Herth FJ; Meister M; Ebert W
    Lung Cancer; 2008 Jun; 60(3):408-15. PubMed ID: 18083270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
    Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
    Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of CYFRA 21-1 in non-small cell lung cancer.
    Hirashima T; Takada M; Komiya T; Nitta T; Masashi K; Masuda N; Matui K; Kikui M; Yasumitsu T; Kawase I
    Anticancer Res; 1998; 18(6B):4713-6. PubMed ID: 9891546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
    Tsai SC; Kao CH; Wang SJ
    Neoplasma; 1996; 43(1):27-9. PubMed ID: 8843956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer.
    Maeda Y; Segawa Y; Takigawa N; Takata I; Fujimoto N
    Intern Med; 1996 Oct; 35(10):764-71. PubMed ID: 8933183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cyfra 21-1 new marker for non-small cell lung cancer].
    Nikliński J; Furman M; Chyczewski L; Chyczewska E; Rogowski F; Jaroszewicz E
    Pneumonol Alergol Pol; 1994; 62(5-6):227-32. PubMed ID: 7522725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.